DexCom (DXCM) Stock Forecast, Price & News

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last twelve months. There are currently 2 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DXCM shares.
View DXCM analyst ratings or view top-rated stocks.

14 analysts have issued 1-year price targets for DexCom's stock. Their DXCM share price forecasts range from $114.00 to $160.00. On average, they anticipate the company's stock price to reach $136.31 in the next twelve months. This suggests a possible upside of 50.9% from the stock's current price.
View analysts price targets for DXCM or view top-rated stocks among Wall Street analysts.

DexCom's stock was trading at $113.24 at the beginning of the year. Since then, DXCM stock has decreased by 20.2% and is now trading at $90.32.
View the best growth stocks for 2023 here.

DexCom saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 16,030,000 shares, a decrease of 5.3% from the August 31st total of 16,920,000 shares. Based on an average daily volume of 3,630,000 shares, the short-interest ratio is currently 4.4 days.
View DexCom's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our DXCM earnings forecast.

DexCom, Inc. (NASDAQ:DXCM) posted its earnings results on Thursday, July, 27th. The medical device company reported $0.34 EPS for the quarter, topping analysts' consensus estimates of $0.22 by $0.12. The medical device company earned $871.30 million during the quarter, compared to analyst estimates of $841.16 million. DexCom had a net margin of 11.18% and a trailing twelve-month return on equity of 22.01%. The business's revenue for the quarter was up 25.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.17 EPS.
Read the conference call transcript.

ETFs with the largest weight of DexCom (NASDAQ:DXCM) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Subversive Mental Health ETF (SANE), Global X Internet of Things Thematic ETF (SNSR), American Century Mid Cap Growth Impact (MID), Fidelity Digital Health ETF (FDHT), iShares U.S. Medical Devices ETF (IHI), Global X Telemedicine & Digital Health ETF (EDOC) and Neuberger Berman Disrupters ETF (NBDS).

DexCom shares split on Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly created shares were payable to shareholders after the market closes on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

DexCom updated its FY 2023 earnings guidance on Friday, September, 15th. The company provided EPS guidance of for the period. The company issued revenue guidance of $3.50 billion-$3.55 billion, compared to the consensus revenue estimate of $3.54 billion.

347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP).

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

DexCom's stock is owned by many different institutional and retail investors. Top institutional shareholders include Bank Julius Baer & Co. Ltd Zurich (12.21%), Baillie Gifford & Co. (4.31%), Sands Capital Management LLC (3.38%), Capital Research Global Investors (2.35%), Geode Capital Management LLC (2.21%) and Jennison Associates LLC (1.88%). Insiders that own company stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Bridgette P Heller, Chad Patterson, Jacob Steven Leach, Jay S Skyler, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Matthew Vincent Dolan, Michael Jon Brown, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal.
View institutional ownership trends.

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DXCM stock can currently be purchased for approximately $90.32.

DexCom (NASDAQ:DXCM) has a market capitalization of $35.03 billion and generates $2.91 billion in revenue each year. The medical device company earns $341.20 million in net income (profit) each year or $0.86 on an earnings per share basis.

The company employs 7,600 workers across the globe.

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The official website for the company is www.dexcom.com. The medical device company can be reached via phone at (858) 200-0200, via email at investorrelations@dexcom.com, or via fax at 858-200-0201.